EGFR+ Lung Cancer
Latest News
Advertisement
Latest Videos
Advertisement
More News
Mark Socinski, MD, explained to a group of physicians at a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation the treatment considerations and decisions he makes when seeing patients with non–small cell lung cancer in the clinic.
During a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation, Paul K. Paik, MD, explained to a group of physicians the treatment considerations and decisions he makes when seeing a patient with non–small cell lung cancer.
Afatinib Demonstrates Manageable Toxicity, Promising Efficacy in TKI-Naive Patients With EGFR+ NSCLC
According to results from a phase IIIb interim analysis, afatinib demonstrated a predictable and manageable toxicity profile and promising efficacy in patients with <em>EGFR</em> mutation-positive non–small cell lung cancer.
Myung-Ju Ahn, MD, discusses the results from the AURA LM trial and the next steps that need to be taken in order to confirm the efficacy that was seen with the lower dose. In addition, she highlights where research in the treatment landscape of advanced NSCLC is headed.
According to findings from an exploratory analysis from the phase III IMpower150 trial presented at the 2019 European Lung Cancer Congress, atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with <em>EGFR</em>-positive metastatic nonsquamous non–small cell lung cancer who have failed on TKI treatment.
Nicolas Girard, MD, discussed the importance of evaluating durvalumab in a real-world setting. In addition, he highlights other questions that remain unanswered in this area, as well as the role of immunotherapy in patients with NSCLC.
A look back at all the FDA news that happened in the month of April 2019, including several new approvals, a priority review, breakthrough designation, and more.
David R. Gandara, MD, discusses the treatment decisions he makes and the data that support his recommendations for treating patients with non–small cell lung cancer
Significantly higher response rates were seen in patients with <em>ALK</em>-positive non–small cell lung cancer who had been treated with at least 1 prior ALK tyrosine kinase inhibitor before receiving lorlatinib and who harbored an <em>ALK </em>resistance mutation compared with those who did not have an <em>ALK </em>mutation.
During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Josephine Louella Feliciano, MD, explained the treatment considerations and decisions she makes when treating a patient with non–small cell lung cancer in the clinic and the data that support these options to a group of physicians.
The approval of the PD-L1 22C3 pharmDX assay has been expanded by the FDA to be used as a companion diagnostic for identifying more patients with stage III or metastatic non–small cell lung cancer who can undergo frontline treatment with pembrolizumab.
According to new findings, tumor mutational burden showed promise as a predictive biomarker for survival benefit in patients with advanced non–small cell lung cancer (NSCLC) treated with the PD-L1 inhibitor durvalumab (Imfinzi) as initial therapy versus chemotherapy, even though there was no difference seen between the 2 treatment groups in the primary analysis of the randomized trial.
Benjamin P. Levy, MD, recently discussed the treatment considerations and decisions he makes when treating patients with non–small cell lung cancer. Levy, the clinical director of medical oncology and associate professor of oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, revealed his treatment decisions to the group based on 2 case scenarios of patients with NSCLC that does not have a genetic driver.
Adding bevacizumab to erlotinib significantly improved progression-free survival compared with erlotinib alone in patients with <em>EGFR</em>-positive, advanced nonsquamous non–small cell lung cancer, suggesting the combination may have the potential to become standard of care for this patient population.
Final data from 2 phase I expansion studies confirmed the efficacy of frontline osimertinib (Tagrisso) in patients with <em>EGFR</em>-positive non­–small cell lung cancer, investigators reported during the 2019 European Lung Cancer Congress.
Alexander Drilon, MD, discussed updated findings with larotrectinib in <em>NTRK</em> fusion–positive tumors and entrectinib in <em>ROS1</em> fusion–positive NSCLC.<br />
The approval for pembrolizumab (Keytruda) has been expanded to include the frontline treatment of patients with stage III non–small cell lung cancer, who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression level of ≥1% and do not harbor <em>EGFR</em> or <em>ALK</em> aberrations.
Combining osimertinib with the MET inhibitor savolitinib demonstrated encouraging antitumor activity and an acceptable safety profile in patients with <em>EGFR</em>-mutant, <em>MET</em>-amplified non–small cell lung cancer who previously received EGFR TKIs, suggesting the regimen could be successful in overcoming <em>MET</em>-driven resistance.
Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Naiyer A. Rizvi, MD, explained, in a presentation at the European Society of Medical Oncology 2019 International Congress on Targeted Anticancer Therapies, that plasma assays for determining TMB are becoming more diagnostically relevant.
A look back at all the FDA news that happened in March 2019, including several new approvals, a clinical hold, an orphan drug designation, and more.
In findings presented during the 2019 AACR Annual Meeting, safety and efficacy was seen with CAR T cells targeting mesothelin-expressing tumors in a preliminary clinical evaluation in patients with malignant pleural disease.
Lurbinectedin (PM1183) monotherapy induced responses in patients with relapsed small cell lung cancer, achieving the primary endpoint of overall response rate in a single-arm phase II trial, according to an announcement from PharmaMar, the company developing lurbinectedin.
The efficacy of osimertinib does not significantly vary according to the body size variables of patients with T790M-positive non–small cell lung cancer who progress on prior EGFR tyrosine kinase inhibitors, according to findings from a new study published in <em>Thoracic Cancer</em>.<br />
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5